Annovis Bio
$1.7500
61
+$0.01+0.57% Thursday 20:00
Statistics
Day High
1.8
Day Low
1.75
52W High
5.5
52W Low
1.54
Volume
1,090,649
Avg. Volume
-
Mkt Cap
46.38M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
18AugExpected
Expected EPS
-0.46
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-49.18MNet Income
Analyst Ratings
17.00Average Price Target
The highest estimate is 17.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow ANVS. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap29.53B
Lilly(Eli) &
LLY
Mkt Cap1.01T
Acadia Pharmaceuticals
ACAD
Mkt Cap3.61B
Anavex Life Sciences
AVXL
Mkt Cap231.68M
Axsome Therapeutics
AXSM
Mkt Cap13.13B
Prothena
PRTA
Mkt Cap426.68M
Alnylam Pharmaceuticals
ALNY
Mkt Cap37.76B
Ionis Pharmaceuticals
IONS
Mkt Cap12.11B
About
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
Show more...
CEO
Dr. Maria L. Maccecchini Ph.D.
Employees
8
Country
United States
ISIN
US03615A1088
Listings
0 Comments
Share your thoughts
FAQ
What is Annovis Bio stock price today?▼
The current price of ANVS is $1.75 USD — it has increased by +0.57% in the past 24 hours. Watch Annovis Bio stock price performance more closely on the chart.
What is Annovis Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Annovis Bio stocks are traded under the ticker ANVS.
Is Annovis Bio stock price growing?▼
ANVS stock has fallen by -1.69% compared to the previous week, the month change is a -14.22% fall, over the last year Annovis Bio has showed a -32.69% decrease.
What is Annovis Bio market cap?▼
Today Annovis Bio has the market capitalization of 46.38M
When is the next Annovis Bio earnings date?▼
Annovis Bio is going to release the next earnings report on August 18, 2026.
What were Annovis Bio earnings last quarter?▼
ANVS earnings for the last quarter are -0.63 USD per share, whereas the estimation was -0.4 USD resulting in a -59.49% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Annovis Bio revenue for the last year?▼
Annovis Bio revenue for the last year amounts to 0 USD.
What is Annovis Bio net income for the last year?▼
ANVS net income for the last year is -49.18M USD.
How many employees does Annovis Bio have?▼
As of June 20, 2026, the company has 8 employees.
In which sector is Annovis Bio located?▼
Annovis Bio operates in the Health & Wellness sector.
When did Annovis Bio complete a stock split?▼
Annovis Bio has not had any recent stock splits.
Where is Annovis Bio headquartered?▼
Annovis Bio is headquartered in Malvern, United States.